Mark Roschewski
MD
Senior Clinician, Lymphoid Malignancies Branch
👥Biography 个人简介
Mark Roschewski at the NCI has contributed to clinical investigations of romidepsin and belinostat — two HDAC inhibitors approved for relapsed/refractory PTCL — and studied mechanisms of response and resistance in T-cell lymphoma. His research at the NCI encompasses clinical trial design, biomarker development, and combination strategies for T-cell malignancies. He is an important voice on lymphoma clinical trial endpoints.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Mark Roschewski 的研究动态
Follow Mark Roschewski's research updates
留下邮箱，当我们发布与 Mark Roschewski（National Cancer Institute (NCI)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment